Platelet Gel In The Treatment Of Severe Scleroderma Skin Ulcers PDF Print E-mail
Tuesday, 02 August 2011 12:01
Dilia Giuggioli, Michele Colaci, Andreina Manfredi, Mariateresa Mariano and Clodoveo Ferri

Systemic sclerosis (SSc) is characterized by microvascular damage and fibrosis of the skin and internal organs. Non-healing skin ulcers, mainly non-venous leg ulcers, represent one of the most challenging complications. Platelet gel (PG) is a hemocomponent containing numerous growth factors, potentially useful for tissue reparation.

This pilot open study aimed to evaluate the effect of PG in 12 SSc patients with skin ulcers resistant to conventional therapies from at least 6 months. PG was applied in the wound bed twice weekly for 2 weeks, then once a week for 12 weeks; in all cases, the ongoing treatments remained unchanged at the time of PG applications.

Skin ulcers were evaluated at 0, 12 and 24 weeks; the patient’s quality of life was also evaluated using the visual analogical scale (VAS) and the health assessment questionnaire (HAQ). During the 6-month follow-up, the skin ulcers consistently improved in 10/12 patients, with complete healing in 4. At the last evaluation, wound size reduced from 23.4 ± 14.9 SD to 2.3 ± 2.2 SD cm2 (p < 0.0001). Patient’s quality of life markedly improved: VAS decreased from 87.08 ± 13.5 to 57.9 ± 12.6; p < 0.0001 and HAQ from 0.73 ± 0.43 to 0.57 ± 0.22; p < 0.0001. PG may represent a novel therapeutic option for SSc skin ulcers refractory to conventional treatments.

For a link to the original article, click here.
 
More articles :

» Rare Diseases Day

Febuary 28th, 2010 was Rare Diseases Day, and it was marked with a variety of events and activities all over the world - as well as with plenty of citizen media and online participation. The goal was to raise awareness about so-called. These are...

» Lidocaine for Systemic Sclerosis: A Double-blind Randomized Clinical Trial

Systemic sclerosis (scleroderma; SSc) is an orphan disease with the highest case-specific mortality of any connective-tissue disease. Excessive deposit in affected tissues is a key for the disease's pathogenesis and comprises most of the clinical...

» Subclinical Atherosclerosis Noted in Diffuse Scleroderma

Patients with diffuse systemic sclerosis (SSc), without any clinical evidence of cardiovascular disease, have indicators of subclinical , according to a study published online Aug. 16 in Arthritis Care & Research.To identify signs of early...

» Ryan Roy Racing to Raise Awareness of Scleroderma

Ryan Roy, of Bellingham, Wash., only has been doing triathlons for two years. In 2010, he completed three races at sprint and Olympic distances. For 2011, in addition to competing in sprint and Olympic triathlons, and his first half marathon in...

» Positive Phase II Results for AIMSPRO In Scleroderma Announced

announced yesterday, positive results from its Double-Blind Placebo-Controlled Phase II Clinical Study evaluating the safety and tolerability of AIMSPRO given as a monotherapy to patients with Late Stage Established Diffuse Cutaneous Systemic...

» Glucosamine, Chondroitin and MSM as Alternative Therapies for Scleroderma

In an article titled, "Glucosamine, Chondroitin and MSM as Alternative Therapies for Scleroderma", Dr. Robert B. Buckingham, M.D., discussed three alternative medicines for treating the pain and the other features associated with . Here, we sought...

Comments  

 
0 #1 michelle oakley 2012-03-27 00:20
i have a ulcer on my abdo which isnt healing which i have 6mths
Report to administrator